TNG Transgene SA

Availability of Transgene's 2023 Universal Registration Document

Availability of Transgene's 2023 Universal Registration Document

TRANSGENE (Paris: TNG) today announced that its Universal registration document for the fiscal year ended December 31, 2023, was submitted to the French stock market authority (Autorité des Marchés financiers – AMF) in ESEF format and registered under the reference D.24-0274.

The 2023 Universal Registration Document is available to the public under the conditions provided by applicable regulations. The document is available on the Company’s website: , in the “Investors/Financial information” section and on the AMF website: -france.org.

It includes:

  • the 2023 annual financial report;
  • the report of the Board of Directors on corporate governance;
  • the statutory auditor’s reports;
  • information on the share buyback program;
  • information related on the auditor’s fees.

The universal registration document also includes information on the Company’s environmental and social responsibility.

Contacts

Transgene:

Lucie Larguier

Chief Financial Officer

+33 (0)3 88 27 91 04

 

Attachment



EN
11/04/2024

Underlying

TNGTransgene SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Transgene SA

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
13h / 58m 13h / 58m 1 FR
 PRESS RELEASE
Free
TNG TRANSGENE SA

Transgene Completes Patient Randomization in Phase 2 Part of Clinical ...

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer Two-year disease-free survival from evaluable Phase 2 patients expected by the end of Q1 2028. Strasbourg, France, April 13, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the completion of patient randomization in the Phase 2 part of the Phase 1/2 clinical trial evaluating TG4050, an individualized neoantigen therapeutic vac...

14h / 52m 1 EN
 PRESS RELEASE
Free
TNG TRANSGENE SA

Transgene annonce la fin de la randomisation des patients de la partie...

Transgene annonce la fin de la randomisation des patients de la partie Phase 2 de l’essai clinique évaluant TG4050 dans le traitement adjuvant des cancers de la tête et du cou Survie sans récidive (DFS) à deux ans attendue au plus tard à la fin du 1er trimestre 2028 pour les patients évaluables de la partie Phase 2 Strasbourg, France, le 13 avril 2026, 8 h 00 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers, annonce aujourd’hui la fin de la randomisation des patients de la partie...

14h / 52m 1 EN
 PRESS RELEASE
Free
TNG TRANSGENE SA

Availability of Transgene’s 2025 Universal Registration Document (URD...

Availability of Transgene’s 2025 Universal Registration Document (URD) Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2025 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 9, 2026, under number D.26-0241. This document, available on the AMF’s website (), can be viewed and downloaded (in PDF format in French and English, and in ESEF format in French only) on Transgene’s website (...

April 9, 2026 1 EN
 PRESS RELEASE
Free
TNG TRANSGENE SA

Document d'Enregistrement Universel 2025

Document d'Enregistrement Universel 2025 Document d'Enregistrement Universel 2025 Pièces jointes

April 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch